28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details
臨床試験数 : 261 / 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04847453 (ClinicalTrials.gov) | September 14, 2021 | 15/4/2021 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis | Recurrent AL Amyloidosis;Refractory AL Amyloidosis | Procedure: Bone Marrow Aspiration and Biopsy;Drug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Venetoclax | National Cancer Institute (NCI) | NULL | Recruiting | 18 Years | N/A | All | 6 | Phase 1 | United States |
| 2 | NCT03618537 (ClinicalTrials.gov) | August 2, 2018 | 2/8/2018 | Ixazomib Maintenance Study in Patients With AL Amyloidosis | Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) Amyloidosis | AL Amyloidosis | Drug: Ixazomib;Drug: Dexamethasone | Memorial Sloan Kettering Cancer Center | Tufts Medical Center;Vanderbilt University Medical Center | Recruiting | 18 Years | N/A | All | 47 | Phase 2 | United States |
| 3 | NCT03283917 (ClinicalTrials.gov) | February 7, 2018 | 13/9/2017 | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | Newly Diagnosed Primary Amyloidosis;Recurrent Primary Amyloidosis;Refractory Primary Amyloidosis | Biological: Daratumumab;Drug: Dexamethasone;Drug: Ixazomib | M.D. Anderson Cancer Center | Janssen Pharmaceuticals;Takeda Pharmaceutical | Recruiting | 18 Years | N/A | All | 20 | Phase 1 | United States |
| 4 | NCT03236792 (ClinicalTrials.gov) | June 12, 2017 | 20/7/2017 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | Phase 1/2 Study Of Ixazomib In Combination With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Immunoglobulin Light Chain AL Amyloidosis | AL Amyloidosis | Drug: Ixazomib;Drug: Cyclophosphamide;Drug: Dexamethasone | Icahn School of Medicine at Mount Sinai | Millennium Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States |